Toxoplasmosis in HIV-Infected Patients
www.UptoDate.com, May, Gandhi, R.T., 2019
Human African Trypanosomiasis
Lancet 375:148-159, 93, Brun,R.,et al, 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Neurocysticercosis Uncovered by Single-Dose Albendazole
NEJM 356:1277-1278, Garcia,H.H.,et al, 2007
Lethal African Trypanosomiasis in a Traveler: MRI and Neuropathology
Neurol 66:1094-1096,962, Braakman,H.M.H.,et al, 2006
Spectrum and Prognosis of Neurologic Complications After Hematopoietic Transplantation
Neurol 67:1990-1997, Denier,C.,et al, 2006
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Cerebral Toxoplasmosis Following Etanercept Treatment for Idiophatic Pneumonia Syndrome after Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT)
Ann Hematol 82:649-653, Gonzalez-Vicent, M.,et al, 2003
Prospective Study of New-Onset Seizures in Patients with Human Immunodeficiency Virus Infection
Arch Neurol 56:609-612, Pascual-Sedano,B.,et al, 1999
Large Cerebral Infarction During Praziquantel Therapy in Neurocysticercosis
Stroke 28:211-213, Bang,O.Y.,et al, 1997
Is the Course of Neurocysticercosis Modified by Treatment with Antihelminthic Agents
Arch Int Med 155:1982-1988, Carpio,A.,et al, 1995
Treatment of Toxoplasmic Encephalitis in Patients with AIDS, Pyrimethamine & Clindamycin vs. Pyrimethamine & Sulfadiazine
Ann Int Med 116:33-43, Dannemann,B.,et al, 1992
Toxicity of Clindamycin as Prophylaxis for AIDS-Associated Toxoplasmic Encephalitis
Lancet 339:333-334, Jacobson,M.A.,et al, 1992
Therapy for Neurocysticercosis
Arch Neurol 49:290-294, Takayanagui,O.M.&Jardim,E., 1992
Toxoplasma Encephalitis in Patients with the Acquired Immunodeficiency Syndrome
Medicine 71:224-239, Renold,C.,et al, 1992
Low-Dose Trimethoprim-Sulfamethoxazole Prophylaxis for Toxoplasmic Encephalitis in Patients with AIDS
Ann Int Med 117:106-111, 163-1641992., Carr,A.,et al, 1992
Efficacy of Atovaquone in Treatment of Toxoplasmosis in Patients with AIDS
Lancet 340:637-638, Kovacs,J.A., 1992
Efficacy and Toxicity of Eflornithine for Treatment of Trypanosoma Brucei Gambiense Sleeping Sickness
Lancet 340:652-655, Milord,F.,et al, 1992
Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome
NEJM 327:1643-1648, Porter,S.B.&Sande,M.A., 1992
Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025
AAV9-Mediated Gene Therapy for Infantile-Onset Pompes Disease
NEJM 392:2438-2446, 2477, Ma,X.,et al, 2025
Autoimmune Encephalitis Misdiagnosis in Adults
JAMA Neurol 80:30-39, Flanagan,E.P.,et al, 2023
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
Looking Beyond the Usual
Delhi J Ophthal doi:7869/djo.555, Shakrawal, J.,et al, 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
A 56-year-old woman with acute vertigo and diplopia
Neurol 90:748-752, Sharma, R.,et al, 2018
Clinicopathologic Conference, Digitalis Toxicity
NEJM 378:1931-1938, Case 15-2018, 2018
Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Case Rep Neurol Med 2018;doi:10.1155/2018/2548528, Shah, S.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Recrudescence of Deficits After Stroke
JAMA Neurol 74:1048-1055, Topcuoglu, M.A.,et al, 2017
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
A 35-Year-Old Man with 2 Episodes of Meningoencephalitis Associated with Flu-Like Illness
Neurol 84:e60-e64, Lewis, S.L., 2015
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Corticosteroid-Induced Paraplegia - A Diagnostic Clue for Spinal Dural Arterial Venous Fistula
JAMA Neurol 72:833-834, Hocker, S., 2015